Increased intestinal permeability to macromolecules and endotoxemia in patients with chronic alcohol abuse in different stages of alcohol-induced liver disease
Roches Evrysdi: 6,30,000/bottle Natcos version: 15,900 97% cheaper Market View: Bullish cue for Natco Pharma Reinforces public health over patent monopoly May trigger fresh debate on pharma IP & pricing Access wins over monopoly, justice for patients, opportunity for innovators
Interleukin-22 protects intestinal stem cells from immune-mediated tissue damage and regulates sensitivity to graft versus host disease
Makes skin radiant and even-toned from head-to-toe
What we know about Eli Lilly's orforglipron If all goes well for Lilly, orforglipron could be up for FDA approval for weight management by the end of 2025, and for type 2 diabetes treatment in 2026
With the right knowledge, the right tools (such as quality insulin syringes), and a conscientious approach, retatrutide can be used safely in a research context
